Molokai Community Health Center (MCHC) in partnership with the U.S. Department of Health and Human Services (HHS) is pleased to announce access to monoclonal antibody (MOAB) therapy , REGENERON, at its facility. This one-time therapy is highly effective in preventing severe disease and hospitalization caused by COVID-19.
In high-risk COVID-19 patients this medication can be given up to 10 days after the first onset of symptoms or positive test. The earlier in infection REGENERON is given, the more effective it is likely to be. This medication is also approved to be used by high risk patients who have not tested positive for COVID-19 as soon as possible after a known COVID exposure
The treatment is given by a one-time injection and authorized for individuals 12 and over with mild to moderate COVID-19 who are not hospitalized, don’t need supplemental oxygen and meet criteria. Receiving treatment earlier in the course of illness may help prevent the development of more severe symptoms that would otherwise require hospitalization. Criteria for therapy are broad and many people are likely candidates who would benefit.
- Monoclonal antibody (mAb) treatment is for people who have tested positive for COVID-19 and are not sick enough to be in the hospital.
- mAb treatment can lower the amount of virus in your body, reduce symptoms and help avoid a trip to the hospital.
- mAb treatment is most effective when received soon after COVID-19 symptoms begin, so it is important to get tested right away.
- mAb treatment is FDA authorized for people who have tested positive for COVID-19 and had mild to moderate symptoms for 10 days or less as well as high-risk patients who have not tested positive for COVID-19 as soon as possible after a known COVID exposure.
- To receive mAb treatment, you must be age 12 or older and meet certain criteria.
- This treatment is effective, but not a replacement for vaccination.
- This treatment is being offered for FREE*, regardless of health insurance or patient status at the Center.
For more information or to be screened to see if you are a candidate for monoclonal therapy, please call us at 808-553-5038, EXT.1.
*Additional service fees that may be determined at time of visit may occur resulting in a co-pay for un-related patient care services. Make sure to discuss this with your Provider if requesting additional evaluations or services.